Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of azenosertib in platinum-resistant high-grade serous ovarian cancer
2022-502983-19-00Phase 2Authorised
- Sponsor
- K-Group Beta, Inc.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of azenosertib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by K-Group Beta, Inc. Planned start Mar 2024; status: authorised.
02
Drugs
azenosertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2022-502983-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502983-19-00.